These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26303222)

  • 1. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients.
    Ohishi T; Fujita T; Suzuki D; Nishida T; Yamamoto K; Okabayashi R; Ushirozako H; Banno T; Matsuyama Y
    Endocr Res; 2017 Aug; 42(3):232-240. PubMed ID: 28318330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study.
    Suzuki T; Nakamura Y; Kato H
    Osteoporos Sarcopenia; 2019 Dec; 5(4):122-127. PubMed ID: 31938731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.
    Ebina K; Kashii M; Hirao M; Hashimoto J; Noguchi T; Koizumi K; Kitaguchi K; Matsuoka H; Iwahashi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Sep; 35(5):571-580. PubMed ID: 27830384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
    Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
    Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
    Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Kaneshiro S; Noguchi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Jan; 35(1):91-98. PubMed ID: 26762133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study.
    Tanaka M; Nakamura Y; Itoh S; Kato Y
    Osteoporos Sarcopenia; 2017 Mar; 3(1):37-44. PubMed ID: 30775501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
    Xu Z; Fan C; Zhao X; Tao H
    Drug Des Devel Ther; 2016; 10():509-17. PubMed ID: 26869769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis.
    Zheng Z; Luo J
    J Orthop Surg Res; 2020 Sep; 15(1):390. PubMed ID: 32907639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients.
    Ohishi T; Fujita T; Suzuki D; Nishida T; Asukai M; Matsuyama Y
    J Bone Miner Metab; 2019 Mar; 37(2):319-326. PubMed ID: 29603071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
    Sugimoto M; Futaki N; Harada M; Kaku S
    Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.